Dr. Paweł Wielgus, Eng., spoke with Puls Biznesu about current plans to raise capital for the construction of a new plant and summarized the company’s current developments. “We are working on responses to EMA inquiries; the deadline for submitting them is the end of the year. We are re-validating the technological route, and an inspection by the Chief Pharmaceutical Inspectorate is expected in November. Everything is progressing well and on schedule,” emphasizes the Bioceltix management board member.
Read more: Potrzebne pieniądze na leki dla psieci. Bioceltix znów idzie po kapitał
MACHINE TRANSLATION